GLP 1 Agonists

This hub provides a comprehensive overview of GLP-1 receptor agonists, semaglutide, and related peptide therapeutics, integrating the latest scientific evidence and clinical perspectives. The linked articles examine the mechanisms of GLP-1–based therapies in weight loss, diabetes management, and beyond, as well as their emerging roles in addressing conditions such as alcohol addiction and menopause-related metabolic changes. Readers will find detailed discussions on efficacy, safety, patient selection, and the comparative potential of novel molecules like berberine. The collection also explores broader trends in peptide therapeutics and the future landscape of targeted treatment. This resource is designed for healthcare professionals, researchers, and individuals seeking authoritative, evidence-based information on GLP-1 and peptide-based interventions.

How Oral GLP-1 Drugs Work For Weight Loss

Discover how next-generation oral GLP-1 therapies are transforming weight management by breaking through the stomach’s toughest barriers and opening the door to powerful, needle-free metabolic treatments.

Overview

Explore authoritative articles on GLP-1, semaglutide, peptide therapeutics, weight loss, diabetes, and emerging treatments. This hub delivers evidence-based insights for clinicians, researchers, and anyone interested in targeted therapies.

Top Nutrients and Habits That Boost GLP-1 Naturally

Wegovy: A Breakthrough in Weight Loss?

The Unexpected Effects of GLP-1 Medications on Women’s Health

The Potential of Peptide Therapeutics in Treating Chronic Diseases

Gut-Brain Axis and Obesity

The Future of Diabetes Treatment

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Multiple Endocrine Neoplasia Type 1 (MEN1)

Who Should Take Weight Loss Injections, and Who Shouldn’t?

Is Berberine Really “Nature’s Ozempic”? What Science Says

The Natural Molecule That Could Rival Ozempic

See more featured articles »

Semaglutide and Weight Loss in Menopause

Recent Advancements in Treatment for Parkinson’s Disease

How Does Semaglutide Work to Lose Weight?

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

What Are Advanced Glycation End Products and Why They Matter

Peptide Therapy: The Future of Targeted Treatment?

The Impact of Glucagon on Diabetes Management

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

Are GLP-1 Drugs the Future of Alcohol Addiction Treatment?

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Latest GLP 1 Agonists News and Research

How GLP‑1 agonists are shaping the future of obesity treatment with Dr Bryony Henderson

GLP-1 agonists are pivotal in obesity care, promoting weight loss and addressing related health issues, with a focus on personalized, holistic treatment.

23 Dec 2025

Fatty diets reprogram hepatocytes and increase liver cancer risk

One of the biggest risk factors for developing liver cancer is a high-fat diet. A new study from MIT reveals how a fatty diet rewires liver cells and makes them more prone to becoming cancerous.

22 Dec 2025

Glucose-lowering drugs may reduce risk of developing epilepsy

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published on December 10, 2025, in Neurology, the medical journal of the American Academy of Neurology.

10 Dec 2025

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Researchers profiled a terminally sterilized probiotic-fermented MFH beverage and identified aporphine alkaloids and flavonoids with favorable predicted ADMET properties. Integrated network pharmacology, molecular docking, and 100-ns MD simulations suggest multi-target engagement of metabolic-inflammatory pathways relevant to obesity and type 2 diabetes.

9 Dec 2025

Sudden cardiac death risk is sharply elevated in people with diabetes

The risk of sudden cardiac death is higher both for people with type 1 and type 2 diabetes, according to a large study published in the European Heart Journal today (Thursday). The increase in risk is especially noticeable among younger adults.

3 Dec 2025

Diabetes drugs linked to slower frailty progression in older adults

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors-such as empagliflozin (Jardiance) and dapagliflozin (Farxiga)-or glucagon-like peptide-1 (GLP-1) receptor agonists-such as semaglutide (Ozempic) and liraglutide (Victoza)-experience slower progression of frailty over one year compared with those starting other diabetes medications.

3 Dec 2025

Obesity-driven estrone emerges as a key driver of deadly postmenopausal breast cancer

A new analysis of research into the most common type of breast cancer has zeroed in on an overlooked hormone that may be responsible for the increased risk of breast cancer death in post-menopausal women with obesity.

2 Dec 2025

WHO releases first guideline on the use of GLP-1 therapies for treating obesity

To address the growing global health challenge of obesity, which affects more than 1 billion people, the World Health Organization (WHO) has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.

2 Dec 2025

Brain recordings reveal why food cravings return despite tirzepatide

Researchers investigate the effects of tirzepatide on food preoccupation by influencing the brain’s mesolimbic circuitry.

1 Dec 2025

Stopping GLP-1 drugs before pregnancy leads to more weight gain

Researchers determine the risk of pregnancy weight gain in patients who were prescribed GLP-1 RAs prior to conception.

1 Dec 2025

Semaglutide helps older adults lose weight without immediate bone loss

Semaglutide shows potential for weight loss in older adults without harming bone density, but longer studies are essential to assess its effects on bone health.

1 Dec 2025

Regenerative medicine offers a pathway toward curing type 1 diabetes

Type 1 diabetes (T1D) is an autoimmune disorder characterized by the specific destruction of insulin-producing pancreatic β-cells.

26 Nov 2025

Obesity-related metabolic stress may affect brain health far earlier than expected

For decades, scientists have known that what harms the body often harms the brain. Conditions such as obesity, high blood pressure and insulin resistance strain the body's vascular and metabolic systems.

25 Nov 2025

GLP-1 discontinuation associated with more weight gain and pregnancy complications

In a study led by researchers at Mass General Brigham, pregnant individuals who stopped taking popular weight loss GLP-1 medications before or early in their pregnancy tended to gain more weight and have higher risks of diabetes and hypertensive disorders during pregnancy, and experienced preterm delivery more so than people who had never taken GLP-1 drugs.

24 Nov 2025

Study finds GLP-1 drugs improve strength and reverse aging biology in mice

Researchers showed that GLP-1 receptor agonism counteracts aging across multiple organs in mice, improving strength and reversing molecular aging signatures without meaningful effects on body weight. These benefits depended largely on hypothalamic GLP-1R signaling and closely mirrored the anti-aging patterns produced by rapamycin.

23 Nov 2025

Oral GLP-1 pill shows strong weight loss and blood sugar benefits in adults with diabetes

A new oral GLP-1 medication can help adults with obesity and Type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by a UTHealth Houston researcher.

20 Nov 2025

Searches for “Ozempic face” surge as people look for filler-based solutions

Public interest in “Ozempic face” rose sharply from 2022 to 2025, mirrored by increased searches for nonsurgical facial filler procedures. Surgical terms showed neutral or negative associations, indicating consumers are primarily exploring filler-based solutions for GLP-1RA-related facial volume loss.

20 Nov 2025

Study compares GLP-1 drug benefits and finds substantial variation in clinical effects

GLP-1 receptor agonists improve glycaemic control and provide renal, metabolic, and selective cardiovascular benefits in people with type 2 diabetes, based on an umbrella review of 17 meta-analyses. However, these agents consistently increase gastrointestinal adverse effects and show important distinctions between class-level outcomes and individual drug effects, particularly for semaglutide.

20 Nov 2025

Study compares the kidney, cardiovascular and mortality risks of three different GLP-1 RAs

Public interest in drugs known as glucagon-like peptide-1 receptor agonists, also called GLP-1 RAs, has surged in recent years, with popular types like semaglutide (sold under brand names like Ozempic and Wegovy) becoming known for their weight-loss effects.

20 Nov 2025

Oral semaglutide delivers real-world drops in blood sugar and weight in diabetes trial

Oral semaglutide delivered meaningful reductions in HbA1c and body weight among GLP-1RA-naïve adults with type 2 diabetes in a Dutch real-world cohort. Lipid levels and blood pressure showed only small changes, reflecting modest cardiometabolic effects outside glucose and weight control.

18 Nov 2025